It will be important in the future to measure replication stress directly in breast cancer patients treated with CDK4/6 inhibitors, and to compare this in patients who are dosed continuously, as with abemaciclib, or in repeated on/off cycles, as with palbociclib/ribociclib (Pernas et al, 2018). The gene discussed is CDK4; the disease is breast carcinoma.